| Course | NR 568 Advanced Pharmacology for the Adult-Gerontology Primary Care Nurse Practitioner |
|---|---|
| Week | 1 |
| Paper type | Discussion post with two replies |
| Length | About 630 words |
| Format | Discussion post with APA 7 citations |
| School | Chamberlain University |
| Program | MSN, Adult-Gerontology Primary Care NP (AGPCNP) |
| Updated | October 2026 |
Free sample paper for NR 568 Week 1
Week 1 Discussion: Initial Post
Citalopram 40 Milligrams for Six Years in a 79-Year-Old: The Order as It Stands, the Fact That Reopens It and Why the Dose Should Come Down to 20
Initial Post
My course patient, a composite drawn from the primary care office where I precept, is a 79-year-old retired railroad conductor who lives with a spouse, still drives to the hardware store and takes ten prescription medicines. This week I want to look at one order. The patient has taken citalopram 40 mg every morning for about six years, started by a previous provider after the death of a sibling, and the depression has been in remission for at least four years.
The fact that reopens this order is age. Citalopram is metabolized in the liver, mainly by CYP2C19 and CYP3A4, and clearance falls in older adults, so the same 40 mg produces higher blood levels at 79 than it did at 73. Higher levels matter because the QT stretch that citalopram causes grows with every milligram. In 2011 and 2012 the Food and Drug Administration advised a maximum of 20 mg daily for patients over 60. A large study of electronic health records found a dose-related prolongation of the QT interval with citalopram (Castro et al., 2013). The patient's most recent electrocardiogram showed a corrected QT of 468 milliseconds, and the patient also takes chlorthalidone, which can lower potassium and magnesium and add to the risk.
Across weeks, the exposure has been steady. Citalopram has a half-life of about 35 hours in younger adults and longer in older ones, so the patient has been at steady state for years. A dose change will reach a new steady state in about a week to ten days.
Of the four possible moves (a smaller amount, a longer interval, removal or continuation with a reason), I argue for a smaller amount: reduce to 20 mg daily. Removal is not my first choice, because the depression responded well and the patient values the stability; an abrupt stop could also cause discontinuation symptoms. A longer interval makes no sense for a drug taken once daily. Continuation at 40 mg is hard to defend given the age, the QT and the chlorthalidone. One caution is honest: a study of veterans found that the warning led to dose reductions but did not show a clear fall in arrhythmias, and lower doses were not associated with more depression relapse (Zivin et al., 2013). That supports the move, but it also means I should not overstate the cardiac benefit.
The plan: citalopram 20 mg daily starting Monday, a PHQ-9 at four and eight weeks, potassium and magnesium checked now, and a repeat electrocardiogram in two weeks.
Question for the group: when an antidepressant has kept someone well for years, how do you explain a dose reduction so that it sounds like protection rather than a loss?
Reply to Jasmine
Jasmine, your patient on digoxin 0.25 mg is a good choice, and you explained clearly why reduced kidney function raises digoxin levels. I would push for the move you would make. Would you reduce to 0.125 mg, extend to every other day, or stop it if rate control is adequate on the beta blocker? Choosing one, and naming the level and the date you would check it, would turn the physiology into an order.
Reply to Nathan
Nathan, your post on long-term zolpidem shows the risk well. I wonder about the timing of exposure: the patient has taken it nightly for three years, so a sudden stop could cause rebound insomnia that looks like the original problem. Would you taper it, and over how many weeks? Adding that would make the removal safer and more likely to stick.
References
Castro, V. M., Clements, C. C., Murphy, S. N., Gainer, V. S., Fava, M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., Iosifescu, D. V., Smoller, J. W., & Perlis, R. H. (2013). QT interval and antidepressant use: A cross sectional study of electronic health records. BMJ, 346, f288. https://doi.org/10.1136/bmj.f288
Zivin, K., Pfeiffer, P. N., Bohnert, A. S., Ganoczy, D., Blow, F. C., Nallamothu, B. K., & Kales, H. C. (2013). Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. American Journal of Psychiatry, 170(6), 642-650. https://doi.org/10.1176/appi.ajp.2013.12030408
The Chamberlain NR 568 Week 1 instructions
This opening discussion usually asks how aging changes the way a familiar drug behaves and what you would do about one patient's existing prescription. Expect the prompt to want a drug, a physiologic change, the effect on the dose and replies to classmates. Name a drug the patient already takes, with its dose and how long it has run. Give the fact that reopens the order, such as reduced clearance, a new interaction or a laboratory finding. Say how exposure behaves over weeks, including how long a change takes to reach steady state. Then choose one of four moves: a smaller amount, a longer interval, removal or continuation with a reason. Close with the recheck and a question for the group.
How the NR 568 Week 1 example is put together
The sample introduces a composite retired railroad conductor on ten prescriptions and narrows to citalopram 40 mg, started after a bereavement. It explains that clearance falls with age, that the QT effect grows with dose, and that chlorthalidone adds electrolyte risk, citing a large records study. A paragraph on exposure notes the long half-life and a new steady state in about a week to ten days. The four moves are weighed openly: removal is set aside to protect a stable remission, a longer interval makes no sense, and continuation is hard to defend. A veterans study is cited honestly as showing no clear arrhythmia benefit. The plan sets the date, the PHQ-9 schedule, electrolytes and an electrocardiogram.
Where the points sit in the NR 568 Week 1 rubric
Marks in this first week usually reward a post aimed at one order, a specific fact that reopens it, attention to timing, a single chosen move and a recheck. The essay on aging physiology that never reaches an order earns the least, so this sample stays with citalopram from start to finish. Naming the QT value and the chlorthalidone links the fact to this patient. Explaining steady state shows awareness of exposure over time. Weighing all four moves and choosing one demonstrates judgment, and citing evidence that tempers the expected benefit shows honesty. Scheduling the PHQ-9 and an electrocardiogram turns the move into a plan. Replies that ask peers to commit to a move or add a taper earn the separate reply points.
NR 568 Week 1 help from the desk
The most frequent weakness here is a general account of how older bodies handle drugs, with no patient and no order. Another is quoting a fact such as slower elimination and then leaving the dose unchanged. Some posts choose removal without considering whether the drug is still helping. Others forget timing, so the reader cannot tell when a change will take effect or when to recheck. Replies that summarize the classmate's post add nothing. Pick one drug the patient takes, name the fact that reopens it, choose one move and schedule the follow-up. Another drug from your own practice can carry the same structure if you send the dose and the patient's age.
Get a NR 568 Week 1 example written to your instructions
Send the Week 1 prompt in your classroom's wording, along with the drug and the patient detail you were given, and a custom example is written to it and returned inside 24 to 48 hours. The first one costs nothing. Which of the four moves you finally argue for stays yours to decide.
More NR 568 papers and AGPCNP samples
- NR 568 Week 2: Medication List Review
- NR 568 Week 3: Drug Interaction Analysis
- NR 568 Week 4: Prescribing Case Analysis
- NR 568 Week 5: Deprescribing Plan
- NR 568 Week 6: Adverse Effect Write-up
- NR 568 Week 7: Polypharmacy Case Study
- NR 568 Week 8: Pharmacotherapy Synthesis
NR 568 Week 1 questions, answered
Can leaving a dose alone really be the answer?
It can, and saying so explicitly is what separates a decision from an oversight. A post that examines the order, names what would have justified a change, and then records that the dose stays as written has taken a position a grader can mark. What earns nothing is silence, where the drug is discussed at length and no conclusion about it ever appears, because a reader cannot tell whether the writer chose or forgot.
What if the case supplies no laboratory values?
Then name the value that would settle it and say what you would do while waiting for one. Primary care work often runs on a result several months old or on nothing at all, and a post that states the missing figure, takes the cautious option and sets a day to revisit it is reasoning properly. Inventing a plausible number, or ignoring that the dose depends on one, both cost points.
Is the kidney the only thing that reopens a dose?
No, and treating it as the only lever narrows the post for no reason. Liver handling, body composition, a low albumin and the arrival of a new entry on the list all change what a standing dose actually delivers. Pick whichever one has moved in your patient and follow it through to a figure. Naming three and following none is the commonest way a first post runs out of room.
Where can I find a free NR 568 Week 1 sample paper?
Above, in full: the citalopram post with its replies to Jasmine and Nathan is the NR 568 Week 1 sample. Another order from your own clinic can be argued the same way.
Why is citalopram reduced to 20 mg in the NR 568 Week 1 post?
The patient is over 60, has a corrected QT of 468 milliseconds and takes a thiazide; citalopram's QT effect rises with dose, and federal advice caps it at 20 mg in this age group.